Apogee Therapeutics, Inc. (APGE) shares surged 19.32% in pre-market trading following strong Phase 2 trial results for APG777, on Monday, July 7, 2025, hitting $56.63. This marks a significant jump from the previous closing price of $47.46 recorded on the prior trading day.
Apogee Therapeutics announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial, a randomized, placebo-controlled study, highlights significant progress in evaluating APG777’s effectiveness.
Two out of every three patients treated with APG777 achieved an EASI-75 response at Week 16, marking the highest response rate for any biologic in a global study to date. These encouraging results reinforce APG777’s potential best-in-class profile for moderate-to-severe atopic dermatitis.
